TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic or hemorrhagic stroke onset 3 - 9 weeks before the recruiting, confirmed by computed tomography or magnetic resonance imaging.~* Moderate to severe motor impairment of an upper limb, defined as a score between 7 - 42 on the Upper Limb Subscale of Fugl Meyer Assessment of Sensorimotor Recovery after stroke.~* Ability to provide written informed consent (patient ou legal representative)~* Ability to comply with the schedule of interventions and evaluations in the protocol.~Exclusion Criteria:~* Severe spasticity at the paretic elbow, wrist or fingers, defined as a score of \> 3 on the Modified Ashworth Spasticity Scale.~* Upper limb plegia~* Uncontrolled medical problems such as end-stage cancer or renal disease~* Pregnancy~* Seizures, except for a single seizure during the first week post stroke~* Pacemakers~* Other neurological disorders such as Parkinson's disease~* Psychiatric illness including severe depression~* Aphasia ou severe cognitive deficits that compromise comprehension of the experimental protocol or ability to provide consent.~* Hemineglect~* Drugs that interfere on cortical excitability, except for antidepressants~* Cerebellar lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active tDCS + robotic therapy + physical therapy (Type: ACTIVE_COMPARATOR): Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks).
- sham tDCS + robotic therapy + physical therapy (Type: ACTIVE_COMPARATOR): Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks).
- sham tDCS + physical therapy + occupational therapy (Type: EXPERIMENTAL): Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG ≤ 1~* Willing to undergo tumor biopsies from injected and distal lesions~* Must have two biopsy accessible lesions:~  * \* one lesion must be ≥10 mm and \<100 mm in longest diameter, accessible for repeated intratumoral (IT) injection and accessible for baseline and on-treatment biopsies.~    * a second (distal) lesion must be accessible for baseline and on-treatment biopsy and must be distinct from the injected lesion.~   * tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate~Exclusion Criteria:~* Patients who require local palliative measures such as XRT or surgery~* Symptomatic or untreated leptomeningeal disease.~* Presence of symptomatic central nervous system (CNS) metastases~* Impaired cardiac function or clinically significant cardiac disease~* Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.~* Active infection requiring systemic antibiotic therapy.~* Known history of Human Immunodeficiency Virus (HIV) infection.~* Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)~* Malignant disease, other than that being treated in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation monotherapy (Type: EXPERIMENTAL): ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
- Dose escalation combination (Type: EXPERIMENTAL): ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Status and Develepment Mental Quality of Life COPD/IPF Inpatients Before and After Pulmonary Rehabilitation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COPD GOLD III-IV~* IPF according Pulmonary Guidelines~Exclusion Criteria:~\< 30% FVC comorbidities with a negativ influence on the prognosis neurological and orthopaedic deficits, which make the participation of the pulmonary rehabilitation impossible non-compliance no written informed consent of the patient

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- COPD patients (GOLD stage III-IV) (Type: EXPERIMENTAL): None
- IPF patients (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who give written consent to participate in the study~* Age between 18 and 65 years old, included.~* Chronic HIV-1 Demonstration of R5 viral tropism (use of CCR5 coreceptors) by genotyping in plasma samples stored~* Patients that are to be treated with intensive chemotherapy for non Hodgkin lymphoma With or without stable antiretroviral therapy~* Patients that are able to understand the purpose of the study and be available for scheduled appointments.~* Both in the case of female and male patients, the patient agrees to use a double barrier method of contraception from the moment of signing the informed consent until 3 months after the end of their participation in the study.~Exclusion Criteria:~* To have planned antiretroviral treatment interruption during the participation in the study~* Hypersensitivity to products used in this study~* To be involved in another clinical trial or received an investigational drug within 3 months prior to the study initiation~* To have contraindications or limitations to perform leukapheresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Control) (Type: NO_INTERVENTION): Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)
- Group 2 (Treatment) (Type: EXPERIMENTAL): Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is aged 6 months to 21 years inclusive.~* Subject is diagnosed with neuroblastoma, hepatoblastoma, osteosarcoma or extracranial germ cell tumors and has not been previously treated with cisplatin or carboplatin.~* Subject is scheduled to receive a chemotherapy regimen that includes a cumulative cisplatin dose of ≥ 200 mg/m2.~* Subject has normal baseline auditory function, defined as ≤ 20 dB from 2000 to 8000 Hz, in both ears and does not have a history of sensorineural hearing loss.~Exclusion Criteria:~* Subject has middle ear effusion upon clinical examination.~* Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study.~* Subject is receiving sodium-thiosulfate or amifostine therapy with chemotherapy.~* Subject is currently participating on a separate otoprotection clinical study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: ACTIVE_COMPARATOR): One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
- Control (Type: NO_INTERVENTION): The ear not receiving OTO-104 will receive no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Microbial Growth in Operative Splash Basins During Total Joint Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting to Keck Hospital of USC or USC Verdugo Hills Hospital for primary total knee arthroplasty or total hip arthroplasty.~Exclusion Criteria:~* Age \< 18 years.~* History of previous total hip arthroplasty or total knee arthroplasty.~* History of previous knee or hip joint infection.~* History of previous allergic reaction to chlorhexidine.~* Known allergy to iodine or shellfish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sterile Water (Type: EXPERIMENTAL): None
- 3.5% betadine (Type: EXPERIMENTAL): None
- 0.05% chlorhexidine gluconate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written Informed Consent~2. ≥18 years of age~3. Diagnosis of HCC~4. Locally advanced HCC~5. Preserved liver function~6. Eastern Cooperative Oncology Group 0 or 1~Exclusion Criteria:~1. Presence of extra-hepatic spread of disease.~2. Macrovascular invasion of lobar portal vein branches or main portal vein.~3. Candidate for surgical resection, transplantation, or local ablation.~4. Prior intra-arterial embolization, chemotherapy or systemic therapy for HCC.~5. Any contraindication for TACE.~6. Platelet count \<50,000/mm3 or international normalized ratio \>1.5.~7. Previous treatment with anthracycline antibiotics (e.g. Doxorubicin) or sorafenib.~8. Unstable coronary artery disease or recent myocardial infarct (i.e. within 1 year).~9. Known ejection fraction \< 50%.~10. Current infections requiring antibiotic therapy.~11. Suffering from a known bleeding disorder.~12. Renal insufficiency (serum creatinine \> 2 mg/dL).~13. Aspartate aminotransferase and/or alanine transaminase \>5 times upper limit of normal.~14. Presence of advanced liver disease.~15. Any contraindication for doxorubicin administration:~16. Any co-morbid condition or social situation, which has a high likelihood of causing poor compliance with the study protocol or jeopardizes the patient's safety.~17. Patient has another primary tumor, with the exception of conventional basal cell carcinoma, superficial bladder cancer, melanoma in situ, or treated prostate cancer currently without biochemical or radiographic evidence of active disease~18. Participation in a clinical trial of an investigational device or drug within 4 weeks of study entry.~19. Pregnant or breast-feeding patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DEB-TACE (Type: EXPERIMENTAL): ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
- Sorafenib (Type: ACTIVE_COMPARATOR): 200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seasonal allergic rhinitis was diagnosed both by history and clinical examination and by the presence at positive skin prick tests~* All participants need to have at least 2 years of seasonal allergic rhinitis symptoms and a positive skin prick test to one or more pollen allergens~Exclusion Criteria:~* use of systemic corticosteroids within past 3 months period,~* active asthma,~* hearing aid usage,~* history of adhesive tape allergy,~* history of metal allergy,~* HIV,~* hepatitis B or C,~* history of hematologic, autoimmune, or malignant disease,~* pregnancy or lactation,~* ear acupressure (EAP) or acupuncture for respiratory disease within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): 34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
- Sham (Type: SHAM_COMPARATOR): 33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patients with intradialytic hypotension~Exclusion Criteria:~* Atrial fibrillation~* Bilateral upper extremity arteriovenous access~* Average plasma sodium \>139

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- standard dialysate sodium (140 mmol/L) (Type: ACTIVE_COMPARATOR): dialysate sodium (140 mmol/L)
- individualized dialysate sodium (Type: EXPERIMENTAL): individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * Metastatic disease~* Scheduled to receive ≥ 1 of the following chemotherapy drugs:~  * Paclitaxel~ * Docetaxel~ * Capecitabine~ * Gemcitabine hydrochloride~    * Concurrent enrollment in the University of Minnesota study Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors (Human Subjects Code 0508M72989) required~ * Albumin-bound paclitaxel (Abraxane)~ * Doxorubicin hydrochloride~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 6 months~* Serum creatinine \< 2.0 mg/dL~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No history of seizures~* No uncontrolled hypertension~* No history of stroke~* No malabsorption syndrome~* No cognitive impairment~* No history of psychiatric disability affecting informed consent or compliance with drug intake~* Able to take oral medication~* Able to complete questionnaire(s) alone or with assistance~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent warfarin~* No concurrent radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV criteria for nicotine dependence with FTND score \> 5.~* Smoke at least 15 cigarettes (3/4 pack) daily (averaged over 1 week, in the past 1 month).~* At the time of initial evaluation, are motivated to quit smoking in the next 30 days.~* Have made at least one unsuccessful attempt to quit smoking in the past year.~* At baseline, have expired breath CO level \> 10.~* Are between ages 18-70 years old.~* Weigh at least 100 lbs (45.5 kg, selegiline dose \< 0.22 mg/kg).~* No previous use of nicotine replacement products in the one month prior to randomization.~* Have the capacity to give informed consent, and are English-speaking.~Exclusion Criteria:~* Have present or past diagnoses of schizophrenia, bipolar disorder, PTSD, BPD or major depressive illness.~* Have abused alcohol or other drugs of abuse (cocaine, opiates, benzodiazepines, etc) in 6 months prior to randomization into the trial (based on clinical evaluation including self-report, and confirmed by positive urine).~* Demonstrate serious medical conditions (i.e. abnormal liver function \[as evidenced by AST, ALT or bilirubin values 2x ULN\], unstable cardiovascular disease, significant blood abnormalities).~* Exhibit or have history of clinical hypertension.~* Exhibit active peptic ulcer disease.~* Are pregnant, are trying to become pregnant, or are currently breastfeeding.~* Are on current medication regimes that include antidepressants, or sympathomimetic agents, or meperidine and other meperidine-opioids which may have interactions with selegiline.~* Known hypersensitivity to selegiline or NRT.~* Are from the same household as another study participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult \> 18 years of age~* Closed fracture~* Isolated injury~* No prior injury to ipsilateral forearm~* Less than or equal to two attempts at reduction~Exclusion Criteria:~* Ipsilateral upper extremity injury~* Open injury or neurovascular compromise~* Greater than two attempts at reduction~* Presentation greater than 24 hours after injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Sugar-tong splint (Type: ACTIVE_COMPARATOR): Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
- Short Forearm Cast (Type: ACTIVE_COMPARATOR): Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues